Author

Mitsugu Kanehira

Observed names: M Kanehira, M. Kanehira, MITSUGU KANEHIRA, Mitsugu KANEHIRA, 兼平, 貢

Observed institutions: Iwate University, Iwate Medical University, Kyoto Prefectural University of Medicine, Iwate Medical University Hospital, Institute of Medical Science, The University of Tokyo, The University of Tokyo, Tokushima University

ORCID: 0000-0001-8811-8158

Observed ORCID: 0000-0001-8811-8158

OpenAlex ID: A5085527385

Predicting Response to Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Neoadjuvant Chemotherapy for Bladder Cancers through Genome-Wide Gene Expression Profiling

2005 · Ryo Takata, Toyomasa Katagiri, et al. · Clinical Cancer Research · 234

Involvement of upregulation of DEPDC1 (DEP domain containing 1) in bladder carcinogenesis

2007 · M Kanehira, Y Harada, et al. · Oncogene · 110

Oncogenic Role of MPHOSPH1, a Cancer-Testis Antigen Specific to Human Bladder Cancer

2007 · Mitsugu Kanehira, Toyomasa Katagiri, et al. · Cancer Research · 104

Cell-Permeable Peptide DEPDC1-ZNF224 Interferes with Transcriptional Repression and Oncogenicity in Bladder Cancer Cells

2010 · Yosuke Harada, Mitsugu Kanehira, et al. · Cancer Research · 99

Validation study of the prediction system for clinical response of M‐VAC neoadjuvant chemotherapy

2006 · Ryo Takata, Toyomasa Katagiri, et al. · Cancer Science · 72

Cancer Peptide Vaccine Therapy Developed from Oncoantigens Identified through Genome-wide Expression Profile Analysis for Bladder Cancer

2012 · W. Obara, R. Ohsawa, et al. · Japanese Journal of Clinical Oncology · 65

Predicting Response to Methotrexate, Vinblastine, Doxorubicin, and Cisplatin Neoadjuvant Chemotherapy for Bladder Cancers Through Genome-Wide Gene Expression Profiling

2006 · R. Takata, T. Katagiri, et al. · The Journal of Urology · 57

Present status and future perspective of peptide‐based vaccine therapy for urological cancer

2018 · Wataru Obara, Mitsugu Kanehira, et al. · Cancer Science · 56

PDF

Prognostic outcomes and safety in patients treated with pembrolizumab for advanced urothelial carcinoma: experience in real-world clinical practice

2020 · Daichi Tamura, Noriaki Jinnouchi, et al. · International Journal of Clinical Oncology · 47

Phase I clinical trial of cell division associated 1 ( CDCA 1) peptide vaccination for castration resistant prostate cancer

2017 · Wataru Obara, Fuminori Sato, et al. · Cancer Science · 45

PDF

Oncogenic Role of Mphosph1, a Cancer-testis Antigen Specific to Human Bladder Cancer

2008 · Mitsugu Kanehira, Toyomasa Katagiri, et al. · The Journal of Urology · 35

Postoperative recurrence detection using individualized circulating tumor DNA in upper tract urothelial carcinoma

2023 · Daichi Tamura, Masakazu Abe, et al. · Cancer Science · 34

PDF

Appropriate preoperative membranous urethral length predicts recovery of urinary continence after robot-assisted laparoscopic prostatectomy

2018 · Daiki Ikarashi, Yoichiro Kato, et al. · World Journal of Surgical Oncology · 32

PDF

TIM3 expression on tumor cells predicts response to anti-PD-1 therapy for renal cancer

2020 · Renpei Kato, Noriaki Jinnouchi, et al. · Translational Oncology · 26

PDF

Eight Year Experience with Studer Ileal Neobladder

2006 · Wataru Obara, Kazumasa Isurugi, et al. · Japanese Journal of Clinical Oncology · 23

Improvement of three-dimensional motion sickness using a virtual reality simulator for robot-assisted surgery in undergraduate medical students: A prospective observational study

2021 · Ryo Takata, Mitsugu Kanehira, et al. · BMC Medical Education · 19

PDF

Effective induction of cytotoxic T cells recognizing an epitope peptide derived from hypoxia-inducible protein 2 (HIG2) in patients with metastatic renal cell carcinoma

2016 · Wataru Obara, Takashi Karashima, et al. · Cancer Immunology Immunotherapy · 19

PDF

Predictive factors for short-term biochemical recurrence-free survival after robot-assisted laparoscopic radical prostatectomy in high-risk prostate cancer patients

2019 · Mitsugu Kanehira, Ryo Takata, et al. · International Journal of Clinical Oncology · 17

Recent progress in immunotherapy for urological cancer

2017 · Wataru Obara, Renpei Kato, et al. · International Journal of Urology · 13

Characteristics of early-onset hematotoxicity of sunitinib in Japanese patients with renal cell carcinoma

2017 · Renpei Kato, Yoichiro Kato, et al. · BMC Cancer · 13

PDF

Pathological complete response to neoadjuvant chemotherapy may improve antitumor immune response via reduction of regulatory T cells in muscle-invasive bladder cancer

2024 · Daiki Ikarashi, Shigehisa Kitano, et al. · Scientific Reports · 9

PDF

Pathological Complete Response to Preoperative Nivolumab Plus Cabozantinib for Renal Cell Carcinoma With Inferior Vena Cava Thrombus: A Case Report

2022 · ARISA MACHIDA, DAIKI IKARASHI, et al. · Cancer Diagnosis & Prognosis · 7

PDF

Analyses of Nivolumab Exposure and Clinical Safety Between 3-mg/kg Dosing and 240-mg Flat Dosing in Asian Patients with Advanced Renal Cell Carcinoma in the Real-World Clinical Setting

2020 · Renpei Kato, Daiki Ikarashi, et al. · Translational Oncology · 7

PDF

Comparison of Step‐Specific Operative Times Between the da Vinci Surgical System and the Hinotori Surgical Robot System in Robot‐Assisted Radical Prostatectomy

2025 · Mitsugu Kanehira, Makoto Moriwaka, et al. · Asian Journal of Endoscopic Surgery · 6

A case of male perineal aggressive angiomyxoma with expressions of female hormone receptors